San Francisco, September 10, 2024 - Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the LSX World Congress 2024 in Boston.
The congress is an international event that gathers leaders from biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology.
Recardio is presenting its latest advancements from its drug-based regenerative therapy clinical development program and will give a future outlook on new therapies and expansion programs.
LSX World Congress is taking place from September 11 to 12 in Boston, USA.
About Recardio
Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.
Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction. This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.
For more information, visit: www.recardio.eu or contact pr@recardio.eu